At 6.6% CAGR, Asia Pacific Cough Drops Market is Projected to be Worth US$ 1,268.96 Million by 2031, says Business Market Insights

According to Business Market Insights research, the Asia Pacific cough drops market was valued at US$ 758.74 million in 2023 and is expected to reach US$ 1,268.96 million by 2031, registering a CAGR of 6.6% from 2023 to 2031. Adoption of innovative marketing strategies and increasing shift toward self-medication are among the critical factors attributed to driving the Asia Pacific cough drops market growth.

Cough drops are over-the-counter pharmaceutical products; they are candy-like lozenges that reduce coughing and relieve the pain of a sore throat. These products are readily available in supermarkets, pharmacies, and convenience stores. Their low cost and widespread availability make them an appealing alternative for anyone seeking a fast fix without the requirement for a doctor's visit or prescription. These are especially appealing to those who want relief while at work, traveling, or going about their regular lives. The internet, healthcare apps, and social media have made it easy to access health information in recent years. Consumers may simply look up common symptoms such as cough and sore throats on various online platforms and learn about over-the-counter remedies such as cough drops. Websites, blogs, and influencers frequently suggest products, giving consumers more confidence in self-medication. Moreover, there is a growing trend of preventative healthcare, in which customers actively seek out ways to manage mild symptoms at home before they worsen. Cough drops are viewed as a quick, simple, and practical approach to relieving cough or sore throat, particularly during the cold and flu season.  

According to an article published in Sage Journals in March 2024, the self-medication prevalence was 66.4% in India; the article cited a community-based cross-sectional study conducted among 440 adults from the urban and rural catchment areas of the country. Most participants reported using medication for fever (45%), cough (40.1%), and cold (31.8%). Allopathy was the most common medicinal system used for self-medication, accounting for 83.2% of participant responses. The study concluded that accessibility and lack of time were common reasons for self-medication. Therefore, the increasing inclination toward self-medication is fueling the cough drops market as consumers seek convenient, effective, and affordable solutions for managing mild symptoms of cough and sore throat.

On the contrary, the inability to provide long-term relief and availability of alternatives hampers the growth of Asia Pacific cough drops market.

By product, the Asia Pacific cough drops market is segmented into gluten free, sugar free, and others. The sugar free held 49.0% share of Asia Pacific cough drops market share in 2023, amassing US$ 371.99 million. It is projected to garner US$ 637.70 million by 2031 to register 7.0% CAGR during 2023–2031.

By application, the Asia Pacific cough drops market is bifurcated into adults and children. The adults held 83.3% share of Asia Pacific cough drops market share in 2023, amassing US$ 632.06 million. It is projected to garner US$ 1,071.46 million by 2031 to register 6.8% CAGR during 2023–2031.

By distribution channel the Asia Pacific cough drops market is bifurcated into offline and online. The offline held 69.8% share of Asia Pacific cough drops market share in 2023, amassing US$ 529.89 million. It is projected to garner US$ 870.78 million by 2031 to register 6.4% CAGR during 2023–2031.

Based on country, the Asia Pacific cough drops market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 28.0% share of Asia Pacific cough drops market in 2023. It was assessed at US$ 212.14 million in 2023 and is likely to hit US$ 360.31 million by 2031, registering a CAGR of 6.8% during 2023–2031.

Key players operating in the cough drops market are Bliss GVS Pharma Ltd, Cipla Ltd, Gepach International, GSK Plc, Mondelez International Inc, Reckitt Benckiser Group Plc, Ricola, Sanofi SA, The Procter & Gamble Co, and Thornton & Ross, among others.

• In September 2024: Cofsils, a brand by Cipla Health Ltd. specializing in sore throat relief, launched a new flavor: Cofsils Mulethi. This lozenge offers the soothing taste of Mulethi (Licorice) and provides relief from sore throat in just five minutes. Cofsils Mulethi joined the existing flavors, including Cofsils Fresh Mint, Cofsils Tulsi Pudina, and popular options like Cofsils Orange, Lemon Honey, and Ginger Lemon.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com